Zacks Small Cap Research – APVO: RAINIER Phase 1b Dose Optimization Study Completion by Year-End 2026
By David Bautz, PhD NASDAQ: APVO READ THE FULL APVO RESEARCH REPORT Business Update Mipletamig Continues to Generate Encouraging Clinical Evidence in Frontline AML Aptevo Therapeutics, Inc. (NASDAQ: APVO) has provided a number of important recent clinical updates that show the potential for mipletamig as a differentiated treatment option for patients with newly diagnosed acute myeloid leukemia (AML) who are








